Surprisingly, for most cancers bearing multiple TTN/MUC16 mutations (e.g., large intestine, lung, and endometrial cancers), mutation rates at all sites were invariably low (bounded by 1%; Figure S32 for TTN, Figure S33 for MUC16), very different from the well-known cancer genes discussed above. This evidence concerns the gene MUC16 and cancer.